Data gathered: November 22
AI Stock Analysis - Viatris (VTRS)
Analysis generated May 4, 2024. Powered by Chat GPT.
Viatris is a healthcare company formed through the merger of Mylan N.V. and Upjohn, a division of Pfizer. It is a global pharmaceutical and life sciences company that specializes in generic, brand name, and over-the-counter products. With a portfolio of more than 1,400 approved molecules, Viatris operates in more than 165 countries and territories, working to empower people worldwide to live healthier at every stage of life.
Stock Alerts - Viatris (VTRS)
 |
Viatris | November 22 News Alert: Viatris fined in Morocco over merger notification, sources say |
|
Viatris | November 20 Business Outlook among employees is down by 4.2% over the last month. |
|
Viatris | November 13 Web Traffic is down by 47% over the last month. |
|
Viatris | November 13 Insider Alert: Campbell Paul is selling shares |
Alternative Data for Viatris
| Alternative Data | Value | 3m Change | Trend | Benchmark |
|---|---|---|---|---|
| Job Posts | 278 | Sign up | Sign up | Sign up |
| Sentiment | 97 | Sign up | Sign up | Sign up |
| Webpage traffic | 99,000 | Sign up | Sign up | Sign up |
| Employee Rating | 76 | Sign up | Sign up | Sign up |
| Google Trends | 64 | Sign up | Sign up | Sign up |
| Patents | N/A | Sign up | Sign up | Sign up |
| 4chan Mentions | N/A | Sign up | Sign up | Sign up |
| Instagram Followers | 8,930 | Sign up | Sign up | Sign up |
| Reddit Mentions | 1 | Sign up | Sign up | Sign up |
| Stocktwits Mentions | 2 | Sign up | Sign up | Sign up |
| Stocktwits Subscribers | 3,692 | Sign up | Sign up | Sign up |
| Twitter Followers | 8,501 | Sign up | Sign up | Sign up |
| Twitter Mentions | 31 | Sign up | Sign up | Sign up |
| News Mentions | N/A | Sign up | Sign up | Sign up |
| Customer reviews | N/A | Sign up | Sign up | Sign up |
| Business Outlook | 68 | Sign up | Sign up | Sign up |
| Linkedin Employees | 16,755 | Sign up | Sign up | Sign up |
About Viatris
Mylan NV is a pharmaceutical healthcare company. The firm engages in the development, license, manufacture, market and distribution of generic, branded generic and specialty pharmaceutical products. It operates through the following geographical segments: North America, Europe and Rest of World. The North America segment develops, manufactures, sells, and distributes pharmaceutical products in tablet, capsule, injectable, transdermal patch, gel, nebulized and cream, or ointment form. The Europe segment operates through subsidiaries in Italy, Germany, the United Kingdom, and Spain. The Rest of World segment comprises of operations in Japan, Australia, China, Brazil, Russia, India, South Africa, Middle East and South East Asia.
| Price | $13.25 |
| Target Price | Sign up |
| Volume | 6,940,000 |
| Market Cap | $15.7B |
| Year Range | $9.95 - $13.25 |
| Dividend Yield | 3.66% |
| PE Ratio | 223.2 |
| Analyst Rating | 0% buy |
| Industry | Drug Manufacturers |
In the news
 |
Press release: Viatris fined £1.5m for failure to comply with CMA orderNovember 22 - Www.gov.uk |
 |
Viatris fined in Morocco over merger notification, sources sayNovember 21 - Investing.com |
 |
Viatris Inc. (VTRS) Management Presents at Jefferies London Healthcare Conference (Transcript)November 20 - SeekingAlpha |
|
Viatris Inc. (VTRS) UBS Global Healthcare Conference (Transcript)November 14 - SeekingAlpha |
 |
Bargain Priced Viatris Reports Strong Q3 Earnings ResultsNovember 7 - SeekingAlpha |
 |
Viatris Inc (VTRS) Q3 2024 Earnings Call Highlights: Strong Revenue Growth and Strategic Debt ...November 7 - Yahoo |
Financial performance View All
| Revenue | Cost of Revenue | Gross Profit | Net Income | ebitda | EPS | |
|---|---|---|---|---|---|---|
| Q3 '24 | 3.75B | 2.29B | 1.46B | 95M | 811M | 0.750 |
| Q2 '24 | 3.8B | 2.35B | 1.45B | -326M | 351M | 0.690 |
| Q1 '24 | 3.66B | 2.16B | 1.5B | 114M | 944M | 0.670 |
| Q4 '23 | 3.84B | 2.24B | 1.6B | -766M | -176M | 0.620 |
| Q3 '23 | 3.94B | 2.25B | 1.69B | 332M | 1.13B | 0.790 |
Insider Transactions View All
| Campbell Paul filed to sell 126,901 shares at $12.9. November 12 '24 |
| Malik Rajiv filed to sell 505,838 shares at $11.7. September 13 '24 |
| Malik Rajiv filed to sell 60,319 shares at $12. August 30 '24 |
| Malik Rajiv filed to sell 160,319 shares at $11.8. August 23 '24 |
Similar companies
| Company | Price | AI Score | |
|---|---|---|---|
 |
Johnson & JohnsonJNJ |
$155.5 0% | 51 |
 |
Eli Lilly and CompanyLLY |
$749.92 0% | 65 |
 |
PfizerPFE |
$25.13 0% | 42 |
 |
AstrazenecaAZN |
$64.26 0% | 70 |
 |
AbbVieABBV |
$171.73 0% | 59 |
Congress Trading View All
| Politician | Filing Date | Type | Size |
|---|---|---|---|
| Rohit Khanna Democrat |
May 6, 24 | Buy | $1K - $15K |
| Rohit Khanna Democrat |
Feb 5, 24 | Sell | $1K - $15K |
| Rohit Khanna Democrat |
Jun 12, 23 | Sell | $1K - $15K |
Read more about Viatris (VTRS) and their ai stock analysis, price prediction, earnings, congress trading, insider transactions, technical analysis, job posts, sentiment, webpage traffic, employee rating, google trends, patents, 4chan mentions, instagram followers, reddit mentions, stocktwits mentions, stocktwits subscribers, twitter followers, twitter mentions, news mentions, customer reviews, business outlook & linkedin employees.
What is the Market Cap of Viatris?
The Market Cap of Viatris is $15.7B.
What is Viatris' PE Ratio?
As of today, Viatris' PE (Price to Earnings) ratio is 223.2.
What is the current stock price of Viatris?
Currently, the price of one share of Viatris stock is $13.25.
How can I analyze the VTRS stock price chart for investment decisions?
The VTRS stock price chart above provides a comprehensive visual representation of Viatris' stock performance over time. Investors can use this chart to identify patterns, trends, and potential support or resistance levels. By examining historical data and recent price movements, investors can make more informed decisions regarding buying, holding, or selling Viatris shares. Our platform offers an up-to-date VTRS stock price chart, along with technical data analysis and alternative data insights.
Does VTRS offer dividends to its shareholders?
Yes, Viatris (VTRS) offers dividends to its shareholders, with a dividend yield of 3.66%. This dividend yield represents Viatris' commitment to providing value to its shareholders through both potential capital appreciation and steady income. Investors considering Viatris in their portfolio should factor in this dividend policy alongside the company's growth prospects and market position.
What are some of the similar stocks of Viatris?
Some of the similar stocks of Viatris are Johnson & Johnson, Eli Lilly and Company, Pfizer, Astrazeneca, and AbbVie.
.